Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.

Intravenous VCN-01 combined with gemcitabine and nab-paclitaxel improves overall survival in metastatic pancreatic ductal adenocarcinoma, meeting primary efficacy endpoints in the FAS population.

• Why it matters: Pancreatic ductal adenocarcinoma has limited treatment options and poor prognosis, highlighting the need for more effective therapies to extend survival and improve patient outcomes.
• What they did: A randomized phase 2b trial assessed two doses of VCN-01 with chemotherapy versus chemotherapy alone in 101 patients, measuring overall survival, progression-free survival, and safety.
• The result: The combination extended median overall survival to 10.8 months and progression-free survival to 7.0 months, with a notable survival rate of 35.5% at 15 months, supporting further phase 3 evaluation.